Literature DB >> 18426893

Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

Esther Calbo1, Montserrat Alsina, Mónica Rodríguez-Carballeira, Josep Lite, Javier Garau.   

Abstract

Bacterial alveolar invasion is followed by an inflammatory response. A systemic extension of the compartmentalized immune response has been described in patients with severe pneumonia. The data suggest that some antimicrobials may induce a differential release of cytokines. We conducted a prospective, randomized study in adult patients with severe pneumococcal pneumonia to measure the effects of ceftriaxone and levofloxacin in the systemic cytokine expression over time. Demographic, clinical characteristics, and severity scores were recorded. The serum concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-6, IL-8, IL-10, and IL-1 receptor agonist were measured at 0, 24, 72, and 120 h. A total of 32 patients were included in the study. Both groups were homogeneous in terms of age, comorbidities, severity of disease, and corticosteroid or statin use. With the single exception of IL-1beta, all cytokines were detected in venous blood. All of the cytokines studied showed a similar pattern of progressive decrease over time. No significant differences in the concentrations of any of the cytokines studied were found, with the exception of TNF-alpha, for which lower concentrations were obtained at 120 h in the levofloxacin group (P = 0.014). Basal oxygen saturation (P = 0.034) and heart rate (P = 0.029) returned to normal values earlier in the levofloxacin arm. We demonstrated that in patients with severe pneumococcal pneumonia pro- and anti-inflammatory responses could be detected in venous blood, representing a systemic extension of the compartmentalized response. Treatment with a beta-lactam agent or a fluoroquinolone has different effects on cytokine production and its systemic expression, impacting the clinical course of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18426893      PMCID: PMC2443896          DOI: 10.1128/AAC.00658-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  The nature of cell wall-derived inflammatory components of pneumococci.

Authors:  A Tomasz; K Saukkonen
Journal:  Pediatr Infect Dis J       Date:  1989-12       Impact factor: 2.129

2.  APACHE II: a severity of disease classification system.

Authors:  W A Knaus; E A Draper; D P Wagner; J E Zimmerman
Journal:  Crit Care Med       Date:  1985-10       Impact factor: 7.598

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  A prediction rule to identify low-risk patients with community-acquired pneumonia.

Authors:  M J Fine; T E Auble; D M Yealy; B H Hanusa; L A Weissfeld; D E Singer; C M Coley; T J Marrie; W N Kapoor
Journal:  N Engl J Med       Date:  1997-01-23       Impact factor: 91.245

5.  Etiology and cytokine expression in patients requiring mechanical ventilation due to severe community-acquired pneumonia.

Authors:  Chieh-Liang Wu; Ming-Cheng Chan; Gee-Chen Chang; Yao-Ling Lee; Chung-Shih Chin; Kai-Ming Chang; Jeng-Yuan Hsu
Journal:  J Formos Med Assoc       Date:  2006-01       Impact factor: 3.282

6.  Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia.

Authors:  Anton A Igonin; Victor W Armstrong; Maria Shipkova; Natalya B Lazareva; Vladimir G Kukes; Michael Oellerich
Journal:  Clin Biochem       Date:  2004-03       Impact factor: 3.281

7.  Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells.

Authors:  Jung-Hyun Choi; Min-Jin Song; Seung-Han Kim; Su-Mi Choi; Dong-Gun Lee; Jin-Hong Yoo; Wan-Shik Shin
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Induction of pulmonary inflammation by components of the pneumococcal cell surface.

Authors:  E Tuomanen; R Rich; O Zak
Journal:  Am Rev Respir Dis       Date:  1987-04

9.  The induction of meningeal inflammation by components of the pneumococcal cell wall.

Authors:  E Tuomanen; H Liu; B Hengstler; O Zak; A Tomasz
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

10.  Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias.

Authors:  A Ortqvist; A Grepe; I Julander; M Kalin
Journal:  Scand J Infect Dis       Date:  1988
View more
  13 in total

Review 1.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

Review 2.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

3.  Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia.

Authors:  Fiona Havers; Anna M Bramley; Lyn Finelli; Carrie Reed; Wesley H Self; Christopher Trabue; Sherene Fakhran; Robert Balk; D Mark Courtney; Timothy D Girard; Evan J Anderson; Carlos G Grijalva; Kathryn M Edwards; Richard G Wunderink; Seema Jain
Journal:  Clin Infect Dis       Date:  2016-05-10       Impact factor: 9.079

4.  Effect of Antibiotic Class on Stroke Outcome.

Authors:  Dannielle Zierath; Allison Kunze; Leia Fecteau; Kyra Becker
Journal:  Stroke       Date:  2015-07-02       Impact factor: 7.914

5.  Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia.

Authors:  S Padrones; C Garcia-Vidal; S Fernández-Serrano; A Fernández; C Masuet; J Carratalà; M Coromines; C Ardanuy; F Gudiol; F Manresa; J Dorca
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-22       Impact factor: 3.267

6.  Levonadifloxacin, a Novel Benzoquinolizine Fluoroquinolone, Modulates Lipopolysaccharide-Induced Inflammatory Responses in Human Whole-Blood Assay and Murine Acute Lung Injury Model.

Authors:  Anasuya Patel; Ganesh V Sangle; Jinal Trivedi; Sushant A Shengule; Deepak Thorve; Mohan Patil; Nitin J Deshmukh; Bhushan Choudhari; Avinash Karade; Sangita Gupta; Sachin Bhagwat; Mahesh Patel
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

7.  The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs.

Authors:  Feray Altan; Duygu Neval Sayin Ipek; Orhan Corum; Simten Yesilmen Alp; Polat Ipek; Kamil Uney
Journal:  Trop Anim Health Prod       Date:  2019-06-23       Impact factor: 1.893

Review 8.  Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune System.

Authors:  Ronald Anderson; Gregory Tintinger; Riana Cockeran; Moliehi Potjo; Charles Feldman
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-25

9.  Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia.

Authors:  Catia Cillóniz; Adrian Ceccato; Cristina de la Calle; Albert Gabarrús; Carolina Garcia-Vidal; Manel Almela; Alex Soriano; José Antonio Martinez; Francesc Marco; Jordi Vila; Antoni Torres
Journal:  PLoS One       Date:  2017-08-07       Impact factor: 3.240

10.  Inflammatory mediators and lung abnormalities in HIV: A systematic review.

Authors:  Breanne M Head; Ruochen Mao; Yoav Keynan; Zulma Vanessa Rueda
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.